Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenZachary R. Chalmers, Garrett M. Frampton|Genome Medicine|2017Cited by 3.7k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Jean Hoffman‐Censits et al.|The Lancet|2016Cited by 3.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersAaron M. Goodman, Razelle Kurzrock, Shumei Kato et al.|Molecular Cancer Therapeutics|2017Cited by 2.4k
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 BlockadeDouglas B. Johnson, Christine M. Lovly, Siraj M. Ali et al.|Cancer Immunology Research|2016Cited by 493
Novel <i>SOX10</i> indel mutations drive schwannomas through impaired transactivation of myelination gene programsErik A. Williams, David A. Solomon, Ajay Ravindranathan et al.|Neuro-Oncology|2023Cited by 31